New Orleans-based Ochsner Health was met with some uncertainty when it launched its pharmacogenomic program in March 2022 and became one of the first health systems to standardize genomic testing.

Pharmacogenomic testing for antidepressants could help reduce the time and cost it takes to find the most effective medication for a patient, according to a new study. Scientists developed a ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window LAS VEGAS -- ...

Rosalind Brown had blood clots in her lungs. For years, her doctors tried to get the dose of a blood thinner just right to prevent the risk of a heart attack or other life-threatening complications ...

Pharmacogenomic testing, a mature and growing aspect of personalized medicine, has demonstrated significant ability to enhance health outcomes and reduce healthcare costs. Since the 1970s, ...

US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer ...

"The most striking finding was the realization that the test wasn't useful most of the time. This is seen in the control condition in which about 20% of patients were started on a medication with a ...

Enable more effective and targeted treatments that address unique needs for patients with pharmacogenomics. The traditional one-size-fits-all approach to medication has long been recognized as a ...

A new U.S. Department of Veterans Affairs study found that pharmacogenomic testing can help providers avoid prescribing antidepressant medications that may have undesirable outcomes. Pharmacogenomics ...

Pharmacogenetic testing, which is used to classify how patients with major depressive disorder (MDD) metabolize medications, reduces adverse drug-gene interactions, new research shows. In a randomized ...